The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy - A prospective, pilot observational study by Ehler, J et al.
RESEARCH ARTICLE
The prognostic value of neurofilament levels
in patients with sepsis-associated
encephalopathy – A prospective, pilot
observational study
Johannes EhlerID1,2*, Axel PetzoldID2,3, Matthias Wittstock4, Stephan Kolbaske4,
Martin Gloger5, Jo¨rg Henschel5, Amanda Heslegrave6,7, Henrik Zetterberg6,7,8,9, Michael
P. Lunn2, Paulus S. Rommer10, Annette Grossmann11, Tarek Sharshar12,13,
Georg Richter1, Gabriele No¨ldge-Schomburg1, Martin Sauer1
1 Department of Anesthesiology and Intensive Care Medicine, University Medical Center Rostock, Rostock,
Germany, 2 Department of Neuroimmunology, Institute of Neurology, University College London, London,
United Kingdom, 3 Moorfields Eye Hospital, The National Hospital for Neurology and Neurosurgery, London,
United Kingdom, 4 Department of Neurology, University Medical Center Rostock, Rostock, Germany,
5 Department of Internal Medicine, Intensive Care Unit, University Medical Center Rostock, Rostock,
Germany, 6 Department of Molecular Neuroscience, Institute of Neurology, University College London,
London, United Kingdom, 7 UK Dementia Research Institute at University College London, London, United
Kingdom, 8 Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the
Sahlgrenska Academy at the University of Gothenburg, Mo¨lndal, Sweden, 9 Clinical Neurochemistry
Laboratory, Sahlgrenska University Hospital, Mo¨lndal, Sweden, 10 Department of Neurology, Medical
University Vienna, Vienna, Austria, 11 Institute for Diagnostic and Interventional Radiology, University
Medical Center Rostock, Rostock, Germany, 12 Department of Neuro-anesthesiology and Intensive Care
Medicine, Saint-Anne Teaching Hospital, Paris-Decartes University, Paris, France, 13 Laboratory of Human
Histopathology and Animal Models, Institut Pasteur, Paris, France
* johannes.ehler@med.uni-rostock.de
Abstract
Sepsis-associated encephalopathy (SAE) contributes to mortality and neurocognitive
impairment of sepsis patients. Neurofilament (Nf) light (NfL) and heavy (NfH) chain levels as
biomarkers for neuroaxonal injury were not evaluated in cerebrospinal fluid (CSF) and
plasma of patients with sepsis-associated encephalopathy (SAE) before. We conducted a
prospective, pilot observational study including 20 patients with septic shock and five
patients without sepsis serving as controls. The assessment of SAE comprised a neuropsy-
chiatric examination, electroencephalography (EEG), magnetic resonance imaging (MRI)
and delirium screening methods including the confusion assessment method for the ICU
(CAM-ICU) and the intensive care delirium screening checklist (ICDSC). CSF Nf measure-
ments in sepsis patients and longitudinal plasma Nf measurements in all participants were
performed on days 1, 3 and 7 after study inclusion. Plasma NfL levels increased in sepsis
patients over time (p = 0.0063) and remained stable in patients without sepsis. Plasma NfL
values were significantly higher in patients with SAE (p = 0.011), significantly correlated with
the severity of SAE represented by ICDSC values (R = 0.534, p = 0.022) and correlated with
a poorer functional outcome after 100 days (R = -0.535, p = 0.0003). High levels of CSF Nf
were measured in SAE patients. CSF NfL levels were higher in non-survivors (p = 0.012)
compared with survivors and correlated with days until death (R = -0.932, p<0.0001) and
PLOS ONE | https://doi.org/10.1371/journal.pone.0211184 January 24, 2019 1 / 17
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Ehler J, Petzold A, Wittstock M, Kolbaske
S, Gloger M, Henschel J, et al. (2019) The
prognostic value of neurofilament levels in patients
with sepsis-associated encephalopathy – A
prospective, pilot observational study. PLoS ONE
14(1): e0211184. https://doi.org/10.1371/journal.
pone.0211184
Editor: Chiara Lazzeri, Azienda Ospedaliero
Universitaria Careggi, ITALY
Received: October 5, 2018
Accepted: January 8, 2019
Published: January 24, 2019
Copyright: © 2019 Ehler et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript.
Funding: The University of Rostock supported the
department of anesthesiology and intensive care
medicine with institutional departmental funds for
biomarker measurements and for EEG recordings.
Competing interests: AP is supported by the
Moorfields Biomedical Research Centre, and the
Dutch MS Research Foundation and received
honoraria from Novartis for QC reading (Passos
functional outcome after 100 days (R = -0.749, p<0.0001). The present study showed for
the first time that Nf levels provide complementary prognostic information in SAE patients
indicating a higher chance of death and poorer functional/cognitive outcome in survivors.
Introduction
During the last decades the main focus of sepsis care has been directed towards short- and
long-term survival of patients [1]. Consequently patient management has improved reducing
the overall mortality [2]. An important contributor to mortality and long-term morbidity is
sepsis-associated encephalopathy (SAE) [3–6]. SAE is defined as a diffuse brain dysfunction
secondary to sepsis and without evidence of a primary CNS infection or encephalopathy due
to other reasons [7]. The pathophysiology of SAE is still unexplained but risk factors are
emerging [8–11]. Structural evidence for brain injury in sepsis comes from imaging and neu-
roanatomy studies [9–13]. Clinical assessment of SAE is hampered by the altered level of con-
sciousness due to sedation and the need for mechanical ventilation [6,14]. Neuropsychiatric
examination, electroencephalography (EEG), neuroimaging and laboratory tests permit to
monitor SAE [15–17]. Diagnostic accuracy especially of clinical examination and EEG moni-
toring, however remain low in more severe cases potentially confounded by the use of sedation
[17]. Furthermore, the need for prolonged registration of EEG to detect abnormalities over
time is not practicable in the ICU setting and previous studies showed no association between
EEG and brain dysfunction detected by CAM-ICU [18]. In this context body fluid biomarkers
may be of diagnostic value [6,19,20]. A common limitation to previous studies on SAE was
that biomarkers investigated are not specific for the neuro-axonal compartment and results
have been contradictory [21–26]. A more specific biomarker for neuro-axonal injury, the neu-
rofilament proteins (Nf) can be accurately measured from the cerebrospinal fluid (CSF) and
blood and consistently correlated with brain injury, disease severity and survival in a range of
neurological diseases [9,27–32]. Nf proteins are an important part of the axonal cytoskeleton
and represent an architectonic stable tube system [30]. They are classified as intermediate fila-
ments of type IV [30]. As a consequence of axonal injury Nf are released into the extracellular
fluid and can be measured by ELISA technique [30]. This is the first study on the value of neu-
rofilament heavy (NfH) and neurofilament light chains (NfL) in cerebrospinal fluid (CSF) and
plasma of patients with SAE. The aim is to evaluate the potential suitability of Nf as biomarkers
to detect SAE, septic brain injury and to predict outcome in patients with sepsis.
Methods
Study design and ethical protocol
We conducted a prospective, longitudinal single-center exploratory study at three ICU at the
university medical center Rostock, Germany. The patient recruitment period was between
May 2012 and November 2016. All patients or their legal representatives signed a written
informed consent form before study inclusion. The study was registered as a clinical trial
(ClinicalTrials.gov: NCT02442986) and was approved by the local ethics board at Rostock Uni-
versity (A 2012–0058).
Inclusion criteria for participants were patients with an age� 18 years and an inclusion
within 24 hours after the beginning of severe sepsis or septic shock according to the sepsis cri-
teria used at that time [33]. Exclusion criteria for all participants were evidence for any preex-
isting neuromuscular disease like diabetic, alcoholic polyneuropathy or inflammatory
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neuropathies. Additionally, patients with a history of CNS diseases like dementia, ischemia or
hemorrhage were excluded. Furthermore, coagulopathy with active bleeding, no informed
consent by legal representatives, high-dose glucocorticosteroid treatment, preexisting renal
replacement therapy and expected death within 12 hours were exclusion criteria.
Participants with an expected length of ICU stay of more than 48 hours but without sepsis
and without brain dysfunction were included as controls. Except for MRI and lumbar punc-
ture these control subjects had the same longitudinal assessment as sepsis patients.
Multimodal assessment protocol for sepsis-associated encephalopathy
Clinical assessment and long-term follow-up. Patients were longitudinally assessed for
their time of ICU and hospital stay by an interdisciplinary team consisting of experienced neu-
rologists and intensivists. Recommended severity of disease scales including the Acute Physiol-
ogy and Chronic Health Evaluation II (APACHE-II) score at ICU admission and the Sepsis-
related Organ Failure Assessment (SOFA) score at study days 1, 3, 7 and 28 were used [34–36].
All ICU patients were treated as recommended by international guidelines [2,33]. The length
of ICU and hospital stay, days on the ventilator and 28- and 100-day survival were recorded
from all participants. The Barthel index (BI) before hospital admittance and at day 100 after
study inclusion was used to assess patients’ activities of daily living and to evaluate patients’
long-term functional outcome [37,38]. A standardized telephone interview with the patients
or their legal representatives was conducted to ascertain the BI at day 100.
Neuropsychiatric assessment. SAE was defined as a diffuse brain dysfunction secondary
to sepsis and without evidence of a primary CNS infection or encephalopathy due to other rea-
sons [7].
All participants were assessed for clinical signs of brain dysfunction by neuropsychiatric
examination within one day after study inclusion by an experienced neurologist (MW). This
included a detailed medical history from the patient or their legal representatives for early clin-
ical signs of brain dysfunction like confusion, agitation or reduced level of consciousness [39–
41]. Furthermore, the evaluation of EEG recordings and the evaluation of CSF results com-
pleted the neuropsychiatric assessment performed by the neurologist. A standardized neuro-
logic examination included brainstem function. Based on this neuropsychiatric assessment the
diagnosis of SAE was made.
Confusion assessment method for the ICU (CAM-ICU) and Intensive Care Delirium
Screening Checklists (ICDSC). The patients’ level of consciousness was assessed by physi-
cians experienced in intensive (MS, JE) and neuro-intensive care (JE) on day 1, 3, 7 and 28
using the Glasgow Coma Scale (GCS) and the Richmond Agitation and Sedation Scale (RASS)
[36,42]. The longitudinal assessment of brain dysfunction was performed using CAM-ICU and
ICDSC as validated scales to detect signs of delirium [9,39–41]. According to recommendation
CAM-ICU was only performed in patients with a RASS above -4. A patient was defined as
CAM-ICU positive if CAM-ICU screening was positive at least at one time point of assessment.
Electroencephalography and magnetic resonance imaging. Within 72 hours after study
inclusion all patients underwent EEG examinations. EEG recordings (ED 14; Madaus Schwar-
zer, Munich, Germany) were performed over a time of 30 mins and were assessed by an expe-
rienced neurologist (MW). Details on the methods of EEG recording and the classification of
EEG findings using the Young scale were described elsewhere [9,43]. Furthermore, a standard-
ized MRI protocol was used in septic patients to detect brain injury in SAE as described in
detail before [9,13]. In brief, septic shock patients were examined by MRI (1.5-T magnet sys-
tem MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany; 3.0-T mangnet system
MAGNETOM Verio, Siemens Healthcare) as soon they were stable for in house transfer. The
Neurofilament levels in patients with sepsis-associated encephalopathy
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extent of white matter hyperintensities (WMH), an imaging marker of septic brain damage,
was assessed by a neuroradiologist (AG) according to a validated scale [13]. This 4-graded
scale describes WMH in the septic brain according to their number and size. The scale com-
prises grade 0 (no lesions), grade 1 (punctiform lesions), grade 2 (patchy or confluent lesions)
and grade 3 (diffuse lesions) [13].
Neurofilament proteins
CSF samples for Nf measurements were derived from patients with clinical evidence for SAE
and were taken by lumbar puncture within 72 hours after study inclusion. This time frame was
set to achieve a hemodynamic stabilization of septic shock patients before lumbar puncture.
Plasma samples were taken at days 1, 3 and 7. Neurofilaments were measured using two vali-
dated in-house developed ELISA kits [32,44,45]. All samples were batch analyzed in duplicates.
The mean intra-assay coefficient of variation in our study was 3.24%.
Statistical analysis
All statistical analyses were performed in SAS (version 9.4). Normality was tested graphically
and using Shapiro–Wilk statistics. Gaussian data were compared using the T-Test and non–
Gaussian data with the non-parametric Wilcoxon test. A two–way unbalanced ANOVA (gen-
eral linear model, GLM) was used for comparing more than two independent variables.
Weighted power calculations were performed for an alpha of 0.5. Correlation analyses were
performed using Pearson’s R for Gaussian and Spearman’s R for non–Gaussian data. Multiple
correlations were corrected by the Bonferroni method.
Results
Patient demographics
Twenty five critically ill ICU patients were prospectively included, 20 patients with sepsis and
five patients without sepsis serving as controls (Fig 1). MRI reports of 13 included patients
were previously published with a focus on neuroaxonal injury in sepsis (9). In the present
study a total of 20 patients with severe sepsis or septic shock, mean (SD) age 66.7 (14.0) years,
eight male and twelve female, and five matched ICU patients without sepsis, mean (SD) age
61.2 (24.7) years, three of them male and two female, were enrolled (Table 1).
The mean BI of the controls (100) was not significantly different from the mean (SD) BI of
the sepsis cohort (92.3 (15.9), p>0.05).
Clinical assessment of sepsis-associated encephalopathy in sepsis and
control patients
SAE was diagnosed in 18 of 20 sepsis patients by neuropsychiatric assessment. CAM-ICU screen-
ing was positive for brain dysfunction in 16 of 20 participants. None of the five control subjects
showed clinical signs of brain dysfunction according to neuropsychiatric assessment, CAM-ICU
or ICDSC screening. Sepsis patients presented significantly higher mean (SD) ICDSC values in
comparison to the control group (ICDSC 3.3 (2.2) in sepsis vs. 0.8 (0.45) in controls, p = 0.025).
Electroencephalography and magnetic resonance imaging in sepsis and
control patients
EEG examination was performed in 24 of 25 patients. EEG was not available in one patient
due to technical problems. The grade of EEG abnormalities differed between sepsis and
Neurofilament levels in patients with sepsis-associated encephalopathy
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control patients (Table 2). None of the sepsis patients showed normal EEG activity (Table 2).
In contrast, the majority of control patients showed normal alpha activity. Unexpectedly, tri-
phasic waves were detected in one young female control patient (case #23) without evidence
for SAE or any CNS disease. The patient refused cranial MRI examination which prevented
further clarification.
WMH were detected in nine out of 13 sepsis patients with available MRI examinations.
Additionally, subacute ischemic lesions were detected in three sepsis patients respectively. All
EEG and MRI data are summarized in Table 2.
Long-term outcome after 100 days
Seven of 25 patients died within 100 days after study inclusion. Six non-survivors belonged to
the sepsis group and one patient to the control group. The mean (SD) BI of sepsis survivors
was lower than the mean (SD) BI of survivors of the control group (78.21 (29.7 vs. 95.0 (10.0),
p>0.05).
Fig 1. Study flow chart showing the prospective patient enrollment. ICU Intensive Care Unit.
https://doi.org/10.1371/journal.pone.0211184.g001
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Plasma neurofilament levels in sepsis and control patients
Plasma NfL and NfH values were compared between 20 sepsis and five control patients. Signif-
icant differences were present for NfL when comparing sepsis and control patients over time.
The mean NfL values at study day 1 were not statistically different between the groups,but
over time NfL plasma values of sepsis patients were significantly higher in comparison to
Table 1. Patient characteristics of 25 study participants.
Patient ICU cohort Age/
Gender
BI before ICU Sepsis condition Sepsis focus APACHE-II/ Worst
SOFA
Ventilation (days)
1 Sepsis 63/F 100 Shock Abdomen 20/18 72
2 Sepsis 82/F 90 Shock Urogenital 29/15 12
3 Sepsis 85/F 95 Severe Sepsis Abdomen 14/16 0
4 Sepsis 73/M 100 Shock Abdomen 42/15 20
5 Sepsis 57/M 100 Shock Abdomen 27/11 2
6 Sepsis 55/M 100 Shock Abdomen 12/6 0
7 Sepsis 80/F 95 Shock Urogenital 24/12 2
8 Sepsis 64/M 100 Shock Soft tissue 11/14 27
9 Sepsis 72/F 35 Shock Urogenital 9/4 0
10 Sepsis 44/M 95 Shock Abdomen 40/8 10
11 Sepsis 76/F 100 Shock Pulmo 39/12 16
12 Sepsis 74/F 90 Shock Pulmo 23/13 9
13 Sepsis 72/F 100 Shock Urogenital 38/10 0
14 Sepsis 75/M 100 Severe Sepsis Urogenital 37/10 2
15 Sepsis 79/F 100 Shock Soft tissue 22/6 1
16 Sepsis 32/M 100 Shock Abdomen 19/9 4
17 Sepsis 54/F 100 Shock Soft tissue 48/11 8
18 Sepsis 55/F 75 Shock Soft tissue 39/14 6
19 Sepsis 60/F 70 Shock Soft tissue 23/12 12
20 Sepsis 81/M 100 Shock Urogenital 38/12 20
21 Control 74/M 100 None n.a. 23/3 1
22 Control 63/M 100 None n.a. 9/5 0
23 Control 18/F 100 None n.a. 14/5 1
24 Control 74/M 100 SIRS n.a. 17/5 0
25 Control 77/F 100 SIRS n.a. 22/7 1
APACHE-II Acute physiology and chronic health evaluation score, BI Barthel index (activities of daily living), F Female, ICU Intensive care unit, M Male, n.a. Not
applicable, SIRS Systemic inflammatory response syndrome, SOFA Sepsis-related organ failure assessment score.
https://doi.org/10.1371/journal.pone.0211184.t001
Table 2. Electroencephalography and magnetic resonance imaging results from 25 study participants.
Patient cohort EEG findings MRI findings
Normal activity Theta waves Delta waves Triphasic waves Burst-suppression pattern WMH present Ischemic lesions present
SAEa 0/18 10/18 8/18 0/18 0/18 9/11 3/11
No SAE 1/2 1/2 0/2 0/2 0/2 0/2 0/2
Controlb 3/4 0/4 0/4 1/4 0/4 n.a. n.a.
EEG Electroencephalography, MRI Magnetic resonance imaging, n.a. Not applicable, WMH White matter hyperintensities, SAE Sepsis-associated encephalopathy.
a MRI reports available from 11/18 SAE patients
b EEG reports available from 4/5 controls.
https://doi.org/10.1371/journal.pone.0211184.t002
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controls (GLM, p = 0.0063, Fig 2). Within the sepsis group plasma NfL levels significantly
increased from day 1, mean (SD) NfL 1723.4 (1711.5) pg/mL to day 7, mean (SD) 5309.6
(5373.9) pg/mL (p<0.001) which was not observed in the control group (day 1, mean (SD)
NfL 1905.2 (1151.9) pg/mL vs. day 7, mean (SD) NfL 3701.3 (1794.8) pg/mL, p>0.05).
Plasma NfH values were not significantly different between sepsis and control patients at
day 1. Within the sepsis group a significant increase was observed from day 1, mean (SD) NfH
17.6 (41.5) ng/mL to day 7, mean (SD) NfH 163.4 (596.0) ng/mL (p = 0.043). This difference
was not present in the control group (day 1, mean (SD) NfH 100.3 (221.4) ng/mL vs. day 7,
mean (SD) NfH 519.9 (666.9) ng/mL, p>0.05).
An overview about the different development of NfL and NfH levels over time is given in
Table 3.
Power calculations on these data indicate that a group size of n = 134 for plasma NfL,
n = 126 for plasma NfH is needed to reach a power of 80% for separating sepsis from
controls.
Fig 2. Longitudinal profile of neurofilament light chains over time in 20 sepsis and five control patients. The NfL levels significantly increased in sepsis
patients over time and remained stable in controls. Bold line indicates the development of mean plasma neurofilament levels over time. NfL Neurofilament
light chains.
https://doi.org/10.1371/journal.pone.0211184.g002
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Plasma neurofilament levels in patients with sepsis-associated
encephalopathy
Nf levels of 16 CAM-ICU positive patients were compared to four CAM-ICU negative
patients. Mean (SD) NfL levels in CAM-ICU negative patients increased from 808.8 (245.2)
pg/ml at day 1 to 1762.8 (370.5) pg/ml at day 7. Mean (SD) NfL levels in CAM-ICU positive
patients significantly increased from 1952.0 (1849.2) pg/ml at day 1 to 6323.0 (5723.3) pg/ml at
day 7 (p = 0.001). This increase over time was significantly stronger in CAM-ICU positive
compared to CAM-ICU negative patients (GLM, p = 0.011, Fig 3). Next we corrected for miss-
ing samples using mixed models which confirmed the above finding (p = 0.0007). Peak con-
centrations of plasma NfL correlated with higher ICDSC values in sepsis patients (R = 0.534,
p = 0.022). Mean (SD) NfH levels in CAM-ICU positive patients were higher at study day 1
(NfH 22.0 (45.6) ng/ml) compared to CAM-ICU negative patients (mean NfH 0.0 ng/ml) and
further increased in CAM-ICU positive patients to a mean value of 211.3 (673.7) ng/ml at day
7, which was not observed in CAM-ICU negative patients (mean NfH 0.0 ng/ml). No signifi-
cant group difference was observed for the development of NfH levels over time (Table 4).
Power calculations on these data indicate that for plasma NfL a group size of n = 10 is
required on day one and of n = 14 on day seven to to reach a power of 80% for separating
CAM-ICU positive from CAM-ICU negative patients.
MRI results were available from 13 sepsis patients. Septic brain injury, represented by dif-
ferent extents of WMH was detected in nine and not detected in four patients. Further details
on MRI results are provided elsewhere (9). Patients with evidence for WMH tended to have
higher plasma NfL values (mean (SD) NfL levels at day 1: 1405.0 (1063.5) pg/ml; at day 3:
2110.1 (1373.7) pg/ml; day 7: 4658.9 (3959.0) pg/ml) compared to patients without WMH
(mean (SD) NfL at day 1: 665.8 (343.6) pg/ml, p>0.05; day 3: 1058.0 (882.1) pg/ml, p = 0.045;
day 7: 1953.3 (1011.4) pg/ml, p>0.05) which correlated with the extent of lesions on MRI (Fig
4). In comparison to patients without WMH a significant increase of plasma NfL levels was
detected in patients with WMH between day 1 and day 7 (p = 0.012).
Mean (SD) NfH levels slightly increased in patients with WMH from 22.9 (53.8) ng/ml at
day 1 to 355.3 (887.0) ng/ml at day 7 (p>0.05) which was completely different to patients with-
out WMH who did not show an increase of NfH levels over time (NfH 0 ng/ml at all three
time points of measurement).
Table 3. Plasma neurofilament levels in sepsis patients and controls.
Neurofilament Light (NfL) Sepsis group
Mean (SD), pg/mL
Patients, No. (%)
(n = 20)
Control group
Mean (SD), pg/mL
Patients, No (%)
(n = 5)
p Valuea
Day 1 1723.4 (1711.5) 20 (100) 1905.2 (1151.9) 5 (100) p>0.05
Day 3 2753.1 (2774.5) 20 (100) 2208.0 (1363.5) 5 (100) p>0.05
Day 7 5309.6 (5373.9) 18 (90) 3701.3 (1794.8) 3 (60) p>0.05
p value day 1 vs. day 7b p<0.001 p>0.05
Neurofilament Heavy (NfH) Sepsis group
Mean (SD), ng/mL
Patients, No. (%)
(n = 20)
Control group
Mean (SD), ng/mL
Patients, No (%)
(n = 5)
p Valuea
Day 1 17.6 (41.5) 20 (100) 100.3 (221.4) 5 (100) p>0.05
Day 3 18.9 (63.2) 20 (100) 163.1 (350.2) 5 (100) p>0.05
Day 7 164.3 (596.0) 18 (90) 519.9 (666.9) 3 (60) p = 0.016
p value day 1 vs. day 7b p = 0.043 p>0.05
No, Number; SD, Standard deviation.
a p values calculated by comparing sepsis patients and controls.
b p values calculated by comparing neurofilament levels day 1 vs. day 7 within each study group.
https://doi.org/10.1371/journal.pone.0211184.t003
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Plasma neurofilament levels, 28-day and 100-day mortality in sepsis. Plasma Nf levels
of four non-survivors at day 28 were compared to 16 survivors. Mean (SD) NfL levels in non-
survivors increased from 2880.5 (3048.4) pg/ml at day 1 to 6724.7 (8367.0) pg/ml at day 7
(p>0.05). In survivors mean (SD) NfL levels at day 1 increased from 1434.1 (1185.6) pg/ml to
5026.6 (4954.9) pg/ml (p = 0.001).
Mean (SD) NfH levels in non-survivors at day 1 increased from 62.0 (77.6) ng/ml to 847.8
(1461.8) ng/ml (p>0.05) compared to survivors with a mean (SD) NfH level of 6.5 (18.0) ng/
ml at day 1 and an increase to 27.6 (78.6) ng/ml (p>0.05).
Six non-survivors at day 100 were compared to 14 survivors. Mean (SD) NfL levels of the
non-survivors significantly increased from 2765.3 (2417.0) pg/ml at day 1 to 6940.6 (6370.6)
pg/ml at day 7 (p = 0.043). In survivors mean (SD) NfL levels increased from 1276.8 (1148.3)
pg/ml at day 1 to 4682.3 (5084.2) pg/ml at day 7 (p = 0.001).
Mean (SD) NfH levels of non-survivors increased from 58.7 (60.5) ng/ml at day 1 to 586.2
(1096.2) ng/ml at day 7 (p>0.05). In survivors mean NfH levels increased from 0 ng/ml at day
1 to 2.1 (7.5) ng/ml at day 7 (p>0.05).
Fig 3. Longitudinal profile of plasma neurofilament light chain levels in 16 sepsis patients with brain dysfunction and four patients without brain
dysfunction. NfL levels significantly increased in patients with brain dysfunction over time which was not observed in patients without brain dysfunction.
Bold line indicates the development of mean plasma neurofilament levels over time. NfL Neurofilament light.
https://doi.org/10.1371/journal.pone.0211184.g003
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Highly elevated cerebrospinal fluid neurofilament levels in patients with sepsis-associ-
ated encephalopathy. CSF samples were available from 12 of 20 sepsis patients. The mean
(SD) time to CSF examination was 2.75 (2.1) days. Mean (SD) levels of NfH were 561.41
(1697.5) ng/ml and 21891.5 (49917.2) pg/ml for NfL (Table 5). In 8 of 20 patients lumbar
puncture could not be performed due to disclaimer from legal representative after study inclu-
sion (n = 4), unsuccessful puncture related to patient specific anatomical reasons (n = 3) and
contraindication due to local soft tissue infection (n = 1).
Correlation of cerebrospinal fluid neurofilament levels with sepsis-associated encepha-
lopathy, 28-day and 100-day mortality. Neuropsychiatric examination diagnosed SAE at
the beginning of sepsis in all twelve patients with CSF analysis. Therefore, we were not able to
compare CSF Nf levels between SAE positive and negative patients. CSF NfL levels were signif-
icantly higher in both 28- and 100-day non-survivors. In three non-survivors at day 28 the
mean (SD) NfL level of 69,986 (94,939.1) pg/ml was significantly higher compared to a mean
(SD) NfL level of 5860 (4027.5) pg/ml of nine survivors (p = 0.021). We measured significantly
higher CSF NfL levels in five non-survivors at day 100 with a mean (SD) NfL level of 45,966.2
(74,840.8) pg/ml compared to seven survivors with a mean (SD) NfL level of 4695.3 (2465.3)
pg/ml (p = 0.012, Fig 5). CSF NfH levels tended to be higher in septic non-survivors at day 28
(mean (SD) NfH level 2038.4 (3387.5) ng/ml) compared to survivors (mean (SD) NfH level of
69.0 (49.7) ng/ml; p>0.05). This trend was confirmed in non-survivors at day 100 with a mean
(SD) NfH level of 1271.6 (2615.7) ng/ml compared to survivors with a mean (SD) NfH level of
54.1 (32.7) ng/ml (p>0.05).
Power calculations on these data indicate that a group size of n = 53 for CSF NfL, n = 72 for
CSF NfH is needed to reach a power of 80% for separating survivors from non-survivors.
Correlation of cerebrospinal neurofilament levels with brain pathology seen on magnetic
resonance imaging. Seven patients with WMH seen on MRI showed significantly higher CSF
NfL levels, mean (SD) 8217.3 (6139.6) pg/ml, compared to two patients without WMH, mean
(SD) CSF NfL 2958.0 (69.3) pg/ml (p = 0.017). No significant difference in CSF NfH levels was
observed between patients with WMH (mean (SD) CSF NfH level 69.2 (23.8) ng/ml) and with-
out WMH seen on MRI (mean (SD) CSF NfH level 35.5 (50.2) ng/ml, p>0.05).
Correlation of cerebrospinal fluid and plasma neurofilament levels with long-term
functional outcome. We observed a negative correlation between CSF NfH levels and BI
Table 4. Plasma neurofilament levels in patients with and without brain dysfunction detect by the Confusion assessment method for the ICU.
Neurofilament Light (NfL) Brain dysfunction
Mean (SD), pg/mL
Patients, No. (%)
(n = 16)
No brain dysfunction
Mean (SD), pg/mL
Patients, No (%)
(n = 4)
p Valuea
Day 1 1952.0 (1849.2) 16 (100) 808.8 (245.2) 4 (100) p>0.05
Day 3 3205.0 (2940.7) 16 (100) 945.5 (265.3) 4 (100) p>0.05
Day 7 6323.0 (5723.3) 14 (87.5) 1762.8 (370.5) 4 (100) p>0.05
p value day 1 vs. day 7b p = 0.001 p>0.05
Neurofilament Heavy (NfH) Brain dysfunction
Mean (SD), ng/mL
Patients, No. (%)
(n = 16)
No brain dysfunction
Mean (SD), ng/mL
Patients, No (%)
(n = 4)
p Valuea
Day 1 22.0 (45.6) 16 (100) 0 4 (100) p>0.05
Day 3 23.7 (70.3) 16 (100) 0 4 (100) p>0.05
Day 7 211.3 (673.7) 14 (87.5) 0 4 (100) p>0.05
p value day 1 vs. day 7b p = 0.043 p>0.05
No, Number; SD, Standard deviation.
a p values calculated by comparing sepsis patients and controls.
b p values calculated by comparing neurofilament levels day 1 vs. day 7 within each study group.
https://doi.org/10.1371/journal.pone.0211184.t004
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before sepsis. A lower BI before hospital admittance was associated with higher CSF NfH levels
(R = -0.490, p = 0.0028), which was neither present for CSF NfL nor for both plasma Nf levels.
Higher CSF NfL (R = -0.749, p<0.0001) and higher plasma NfL levels (R = -0.535, p = 0.0003)
correlated with a lower BI at day 100 representing a poorer clinical outcome of these patients.
Additionally, a link to patient outcome was observed by correlating CSF NfH and NfL as well
as plasma NfH values with the time to death in non-survivors. Higher Nf levels were associated
with shorter survival of patients (Table 6).
Discussion
This prospective longitudinal exploratory study was conducted to evaluate the prognostic
value of Nf levels in patients with SAE. Nf levels are known to be increased in several disorders
with neuropsychiatric symptoms [27,31,46]. The potential value for SAE has not yet been
investigated. Preexisting studies on SAE analyzed non-specific biomarkers like interleukin-6,
neuron-specific enolase (NSE) or S100B protein [19, 21–23,47,48,49]. The results were found
Fig 4. Development of plasma neurofilament light chain levels in patients with no brain lesions and brain lesions seen on magnetic resonance imaging
in sepsis. No difference in the plasma NfL increase over time between septic patients with and without brain lesions seen on MRI. Bold line indicates the
development of mean plasma neurofilament levels over time. NfL Neurofilament light chain, MRI Magnetic resonance imaging.
https://doi.org/10.1371/journal.pone.0211184.g004
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Table 5. Neurofilament levels in cerebrospinal fluid of twelve sepsis patients.
Patient/
Study code
Study days to LP Cell count
in Mpt/l
(Ref <5 Mpt/l)
Protein
in mg/l
(Ref 150–450 mg/l)
CSF NfH
in ng/ml
CSF NfL
in pg/ml
1 8 1 324 65.0 4908
2 2 1 561 87.2 9425
4 3 1 353 0 2909
6 2 3 302 25.2 2166
7 2 3 245 85.5 9822
9 2 1 209 53.9 4864
10 3 2 453 71.0 3007
11 1 3 326 79.9 20704
14 1 2 373 51.7 5961
15 3 3 282 177.5 14965
18 2 1 151 5949.9 179432
19 5 1 232 89.8 4535
LP Lumbar puncture, Mpt/l Megaparticels/liter, NfH Neurofilament heavy chain, NfL Neurofilament light chain, Ref Reference range.
https://doi.org/10.1371/journal.pone.0211184.t005
Fig 5. Cerebrospinal fluid neurofilament light chain levels in seven survivors and five non-survivors of sepsis. Significantly higher NFL levels were
observed in non-survivors compared to survivors of sepsis. NfL Neurofilament light chain.
https://doi.org/10.1371/journal.pone.0211184.g005
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to be controversial [19,48,49]. Our group is first to analyze the prognostic value of CSF and
plasma NfH and NfL levels in SAE patients which might have importance for the prediction of
long-term neurological sequelae and survival in sepsis. Biomarker research on SAE is neces-
sary as most septic shock patients are sedated and mechanically ventilated and are not easily
assessed for clinical signs of SAE [6,16,43]. Diagnostic measures to evaluate the extent of septic
brain injury, as cerebral MRI or diffusion tensor imaging (DTI), are not universally available
and require resources [50,51]. Specific markers of neuroaxonal injury in SAE could help to
monitor SAE and to predict neurological outcome.
The highly elevated Nf levels in patients with SAE impressively underline the occurrence of
brain injury in sepsis patients [9,10,13,52,53]. As we performed lumbar puncture early during
the course of sepsis a close temporal relationship between the occurrence of septic shock and
septic brain injury has to be suspected. The extent of brain injury was confirmed by MRI dur-
ing study follow-up, which was significantly correlated to elevated NfL levels. Both, MRI and
Nf results support an early start of sepsis treatment and a rapid hemodynamic stabilization of
septic shock patients to prevent CNS and multiple organ failure. This is strikingly obvious
with a look at the correlation of CSF Nf levels with time to death in non-survivors. Addition-
ally CSF and plasma NfL levels significantly correlated with BI at day 100. Higher NfL values
were associated with a poorer long-term functional outcome of survivors, which underlines
the relevance of SAE and the prognostic value of NfL levels. We did not find a correlation
between BI before sepsis and BI at day 100 after sepsis which might have been seen otherwise
as a confounding factor.
Some limitations of the present study have to be mentioned. The number of study partici-
pants was low, which was a consequence of our strict exclusion criteria (a combination of
peripheral and central nervous system diseases) for this single-center study. As SAE is a diag-
nosis of exclusion, we did not include patients with a preexisting neurological disease to pre-
vent a main inclusion bias and to be able to evaluate the development of Nf levels in SAE over
time as precise as possible. All patients finally included were otherwise examined by multi-
modal diagnostics. Our standard MRI examinations might still have underestimated the extent
of brain injury of SAE patients. DTI, which was not available for our investigation would have
been more accurate to visualize neuroaxonal injury [50].
The temporal relationship between onset and progression of sepsis and development of
brain injury is supported by the longitudinal profile of the plasma Nf levels presented here. No
Table 6. Spearmen’s correlation analysis for cerebrospinal fluid and plasma NfH and NfL values.
Parameter Cerebrospinal fluid Plasma
NfH NfL NfH NfL
BI before sepsis R = -0.490
p = 0.0028
p>0.05 p>0.05 p>0.05
BI at day 100 p>0.05 R = -0.749
p<0.0001
p>0.05 R = -0.535
p = 0.0003
Days on ICU p>0.05 p>0.05 p>0.05 p>0.05
Days in hospital R = 0.571
p = 0.007
p>0.05 p>0.05 p>0.05
Days on ventilator p>0.05 p>0.05 p>0.05 p>0.05
Days until death of non-survivors R = -0.657
p = 0.011
R = -0.932
p<0.0001
R = -0.658
p = 0.011
p>0.05
BI Barthel index, ICU Intensive care unit, NfH Neurofilament heavy chains, NfL Neurofilament light chains, n.s. not significant, SOFA Sepsis-related organ failure
assessment.
https://doi.org/10.1371/journal.pone.0211184.t006
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differences of Nf levels were measured at study day 1 between sepsis and control patients,
which is in agreement with earlier studies showing that NfL is a slow marker reaching its maxi-
mum 10–14 days following traumatic brain injury [54]. This is also important as the compara-
ble basal Nf levels were not primarily different between both groups, which could have been a
confounder. Over time, the NfL levels increased in SAE patients, particularly so in patients
with a positive CAM-ICU and severe SAE as indicated by ICDSC. This is relevant as plasma
Nf might act as biomarkers to detect and monitor SAE in septic shock patients. NfL levels in
CSF and by tendency in plasma were significantly higher in patients with brain injury seen on
MRI. Recently our group demonstrated evidence for two distinct patterns of neuroaxonal
injury in sepsis with ischemia and diffuse axonal injury as relevant pathomechanisms [9]. The
results of the present study support the diagnostic role of Nf measurements to detect brain
injury in sepsis and might support their suitability as potential biomarkers of neuroaxonal
injury in SAE patients. This is supported by previous immunohistochemistry findings from
human septic brain tissue [9]. We reported on the disruption of white matter axons in post-
mortem brains of sepsis patients indicated by staining for nonphosphorylated NfH chains [9].
Immunohistochemistry gave clear evidence for axonal degeneration in sepsis which supports
the diagnostic role of Nf measurements in SAE patients.
Conclusion
This is the first study on the relevance of neurofilament heavy (NfH) and neurofilament light
chains (NfL) in cerebrospinal fluid (CSF) and plasma to detect SAE and to predict outcome in
patients with sepsis. This prospective, longitudinal, registered study showed that NfL and NfH
levels were found to be highly elevated in plasma and CSF of patients with SAE. Nf levels in
sepsis correlated with the clinical appearance of SAE, the extent of neuroaxonal injury seen on
MRI and with survival. Power calculations indicate that future studies on prediction of sepsis
survival will require larger sample sizes compared to studies focused on cognitive/functional
outcome in survivors. Given the difficulty in obtaining CSF samples in septic shock patients,
the modest gain for study size calculation and the methodological developments we suggest
future studies to focus on longitudinal plasma NfL and NfH levels using fourth generation
immunoassays.
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